A first-in-human study of MIL95, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors and lymphomas

被引：0
|
作者：
Zhang, Qingyuan
Liu, Aiguo
Shi, Jianhua
Cai, Qingqing
Qu, Zerui
Liu, Sijun
Song, Yuqin
机构：
[1] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[2] Anhui Jimin Canc Hosp, Hefei, Peoples R China
[3] Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[5] Beijing Mabworks Biotech Co Ltd, Beijing, Peoples R China
[6] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14513
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
    J. Mateo
    J. Berlin
    J. S. de Bono
    R. B. Cohen
    V. Keedy
    G. Mugundu
    Lianglin Zhang
    A. Abbattista
    C. Davis
    C. Gallo Stampino
    H. Borghaei
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1039 - 1046
  • [22] First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
    Sikic, Branimir, I
    Lakhani, Nehal
    Patnaik, Amita
    Shah, Sumit A.
    Chandana, Sreenivasa R.
    Rasco, Drew
    Colevas, A. Dimitrios
    O'Rourke, Timothy
    Narayanan, Sujata
    Papadopoulos, Kyriakos
    Fisher, George A.
    Villalobos, Victor
    Prohaska, Susan S.
    Howard, Maureen
    Beeram, Muralidhar
    Chao, Mark P.
    Agoram, Balaji
    Chen, James Y.
    Huang, Jie
    Axt, Matthew
    Liu, Jie
    Volkmer, Jens-Peter
    Majeti, Ravindra
    Weissman, Irving L.
    Takimoto, Chris H.
    Supan, Dana
    Wakelee, Heather A.
    Aoki, Rhonda
    Pegram, Mark D.
    Padda, Sukhmani K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (12) : 946 - +
  • [23] Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors
    Jayson, GC
    Mullamitha, S
    Ton, C
    Valle, J
    Saunders, M
    Munteanu, MC
    Jang, H
    Trikha, M
    Davis, HM
    Beckman, RA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 224S - 224S
  • [24] Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors
    Jayson, GC
    Mullamitha, S
    Ton, C
    Valle, J
    Jackson, A
    Julyan, P
    Munteanu, MC
    Davis, HM
    Lang, Z
    Beckman, RA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 220S - 220S
  • [25] A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers
    Sikic, Branimir I.
    Lakhani, Nehal
    Patnaik, Amita
    Shah, Sumit A.
    Chandana, Sreenivasa R.
    Rasco, Drew
    Colevas, A. Dimitrios
    O'Rourke, Timothy
    Narayanan, Sujata
    Papadopoulos, Kyriakos
    Fisher, George A.
    Villalobos, Victor
    Prohaska, Susan S.
    Howard, Maureen
    Beeram, Muralidhar
    Chao, Mark P.
    Agoram, Balaji
    Chen, James Y.
    Huang, Jie
    Axt, Matthew
    Liu, Jie
    Volkmer, Jens-Peter
    Majeti, Ravindra
    Weissman, Irving L.
    Takimoto, Chris H.
    Supan, Dana
    Wakelee, Heather A.
    Aoki, Rhonda
    Pegram, Mark D.
    Padda, Sukhmani K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] A PHASE 2, MULTI-ARM STUDY OF ANTI-CD47 ANTIBODY, MAGROLIMAB, IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Subbiah, Vivek
    Vaishampayan, Ulka
    Puri, Sonam
    Lin, Lanjia
    Chao, Mark
    Ramsingh, Giri
    Kummar, Shivaani
    Strauss, James
    Patel, Sandip
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A554 - A554
  • [27] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
    Shitara, Kohei
    Uehai, Satoshi
    Shichino, Shigeyuki
    Aoki, Hiroyasu
    Ogiwara, Haru
    Nakatsura, Tetsuya
    Suzuki, Toshihiro
    Shimomura, Manami
    Yoshikawa, Toshiaki
    Shoda, Kayoko
    Kitano, Shigehisa
    Yamashita, Makiko
    Nakayama, Takayuki
    Sato, Akihiro
    Kuroda, Sakiko
    Wakabayashi, Masashi
    Nomura, Shogo
    Yokochi, Shoji
    Ito, Satoru
    Matsushima, Kouji
    Doi, Toshihiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 : 195
  • [29] Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
    Tolcher, Anthony W.
    Gordon, Michael
    Mahoney, Kathleen M.
    Seto, Anna
    Zavodovskaya, Marianna
    Hsueh, Chia-Hsiang
    Zhai, Shuyan
    Tarnowski, Thomas
    Jurgensmeier, Juliane M.
    Stinson, Susanna
    Othman, Ahmed A.
    Chen, Tianling
    Strauss, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [30] A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
    Herbst, Roy S.
    Kurzrock, Razelle
    Hong, David S.
    Valdivieso, Manuel
    Hsu, Cheng-Pang
    Goyal, Lovely
    Juan, Gloria
    Hwang, Yuying C.
    Wong, Susan
    Hill, John S.
    Friberg, Greg
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5883 - 5891
12345